Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

LumiraDx Receives FDA EUA for the LumiraDx SARS-CoV-2 Antigen Test

LumiraDx, the next-generation point of care diagnostic company, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the LumiraDx SARS-CoV-2 antigen test, which will help meet the global challenge of delivering fast and cost-efficient COVID-19 tests in community care settings.

LumiraDx SARS-CoV-2 antigen test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application in symptomatic patients. In clinical studies, the LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive agreement versus PCR in patients tested within 12 days of the onset of symptoms, making it the fastest, most sensitive antigen point of care test currently commercially available.

“Actionable diagnostic results at the point of care lead to better health outcomes,” said Ron Zwanziger, LumiraDx CEO. “Now that the FDA EUA has been received, we are working with health systems, major retail clinics, and employers to get our Platform to healthcare providers quickly to utilize in their testing programs.”

The company plans to begin shipping COVID-19 antigen tests by the end of the month, expects to produce 2 million tests in September, and will ramp to 10 million tests produced in December.

The LumiraDx Platform simplifies, scales down, and integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point-of-care instrument that can be easily used in community care settings. The platform consists of a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the cloud and hospital IT systems. It is designed to offer:

  • Lab comparable performance at point of care in minutes – Each test is developed and validated against its respective lab reference standard, which we believe gives healthcare providers the benefit of both lab comparable performance and real-time results.
  • Broad menu of tests on a single instrument – The platform offers an INR (International Normalized Ratio) test for the management of anticoagulation patients in Europe under CE Mark. The company has a pipeline of over 30 assays across cardiovascular, infectious disease, diabetes, and coagulation disorders with the capability to run immunoassay, chemistry, molecular and other technologies, as well as multiple sample types using a single platform and workflow.
  • Low cost of ownership – The LumiraDx instrument aims to lower the cost per reportable result by offering a variety of low-cost test strips on a single instrument and associated savings including reduced cost of training, maintenance, and supplies.
  • High-quality assurance – The Platform performs more than 30 quality checks during its operation, with performance referenced to standard laboratory methods.

LumiraDx COVID-19 Antigen and Antibody Tests on a Single Platform

In addition to the antigen test, the LumiraDx SARS-CoV-2 antibody test, for use with the LumiraDx Instrument, will shortly be submitted to the FDA for EUA review.

LumiraDx EUA for Fast Lab Solution: LumiraDx recently also received a EUA for its molecular lab reagent kit LumiraDx SARS-CoV-2 RNA STAR, a Fast Lab Solution that utilizes LumiraDx’s innovative qSTAR amplification technology in an accessible high-throughput format with open molecular systems to improve efficiency and speed. LumiraDx SARS-CoV-2 RNA STAR reduces the amplification step of the PCR process from approximately one hour down to 12 minutes.

EUA Status of LumiraDx SARS-CoV-2 Ag test and LumiraDx SARS-CoV-2 RNA STAR

The LumiraDx SARS-CoV-2 Ag test and the LumiraDx SARS-CoV-2 RNA STAR have not been cleared or approved by FDA. The LumiraDx SARS-CoV-2 Ag test has been authorized by the FDA under an EUA only for the detection of SARS-CoV-2 nucleocapsid protein. LumiraDx SARS-CoV-2 RNA STAR has been authorized by the FDA under an EUA only for the detection of nucleic acid from SARS-CoV-2. They have not been authorized for use to detect any other viruses or pathogens.

The tests are authorized in the United States for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy